TPP Matches Chinese Pharma & Capital With Western Assets
Executive Summary
Finding the right partner to enter the Chinese pharma market or access Chinese capital is not a trivial exercise for Western companies. Speaking at the 2018 Biotech Showcase, Tony Chu, founder and managing partner of TPP Healthcare, told Scrip that the advisory company was established to help Western companies achieve their Chinese goals. The sweet spot is late-stage assets for joint venturing or cash thirsty biotechs with programs focused on Asia Pacific health challenges.